« Back
Home /
Vicagrel

Vicagrel

Item no.	HY-118284-5mg
Manufacturer	MedChem Express
CASRN	1314081-53-2
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]French, et al. Method for preparing vicagrel. Patent. WO2014040498A1. \|[2]Jiaqi Shan, et al. Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. J Med Chem
Smiles	O=C(OC)[C@@H](N1CCC2=C(C=C(OC(C)=O)S2)C1)C3=CC=CC=C3Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1314081-53-2
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	P2Y Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	379.86
Product Description	Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease[1][2].
Manufacturer - Research Area	Cardiovascular Disease
Solubility	DMSO: 250 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein
Isoform	P2Y12 Receptor
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-118284-5mg-safety-datasheet.pdf